Brokerages forecast that VIVUS, Inc. (NASDAQ:VVUS) will report ($0.13) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for VIVUS’s earnings. VIVUS reported earnings of ($0.11) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 18.2%. The business is expected to issue its next earnings report on Thursday, August 3rd.

On average, analysts expect that VIVUS will report full year earnings of ($0.39) per share for the current fiscal year. For the next year, analysts expect that the company will post earnings of ($0.45) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for VIVUS.

VIVUS (NASDAQ:VVUS) last posted its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.12. The business had revenue of $27.01 million during the quarter. VIVUS had a net margin of 25.71% and a negative return on equity of 445.42%.

Separately, Zacks Investment Research upgraded shares of VIVUS from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Monday, July 17th.

A number of large investors have recently made changes to their positions in VVUS. Bank of New York Mellon Corp raised its stake in shares of VIVUS by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 3,694 shares during the period. Russell Investments Group Ltd. raised its stake in shares of VIVUS by 84.8% in the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 68,200 shares during the period. Nine Chapters Capital Management LLC bought a new stake in shares of VIVUS during the first quarter worth about $113,000. Oxford Asset Management raised its stake in shares of VIVUS by 76.6% in the first quarter. Oxford Asset Management now owns 587,535 shares of the biopharmaceutical company’s stock worth $658,000 after buying an additional 254,912 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of VIVUS by 164.7% in the first quarter. Acadian Asset Management LLC now owns 1,075,430 shares of the biopharmaceutical company’s stock worth $1,205,000 after buying an additional 669,165 shares during the period. 34.62% of the stock is owned by institutional investors and hedge funds.

VIVUS (NASDAQ:VVUS) traded down 2.52% during midday trading on Thursday, reaching $1.16. 120,651 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $1.21 and a 200 day moving average price of $1.13. The company has a market cap of $122.59 million, a price-to-earnings ratio of 3.52 and a beta of 0.85. VIVUS has a 12-month low of $0.93 and a 12-month high of $1.47.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/27/0-13-eps-expected-for-vivus-inc-nasdaqvvus-this-quarter.html.

VIVUS Company Profile

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Get a free copy of the Zacks research report on VIVUS (VVUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.